logo
Palantir raises annual revenue forecast again on surging AI demand

Palantir raises annual revenue forecast again on surging AI demand

Yahoo04-08-2025
(Reuters) -Palantir Technologies on Monday raised its forecast for annual revenue for the second time this year, expecting robust demand for its artificial intelligence-linked services from businesses and governments.
The data analytics and defense software firm projected revenue in the range of $4.14 billion to $4.15 billion for 2025, up from its earlier forecast of between $3.89 billion and $3.90 billion.
The raised forecast is also above analysts' average estimate of $3.90 billion, according to data compiled by LSEG.
Palantir, which was initially backed by the CIA, has capitalized on its expertise in managing and analyzing data to help train and run new AI apps using its platforms.
Shares of the Denver, Colorado-based company rose more than 2% in extended trading.
Its shares have more than doubled in value this year, far outpacing the 6% gain for the benchmark S&P 500, as investors bet on its ability to benefit from the proliferation of AI technology and government spending on defense tech.
Palantir, co-founded by tech billionaire Peter Thiel, said it now expects revenue derived from U.S. businesses to come in above $1.30 billion, up from its earlier guidance of more than $1.18 billion.
They nearly doubled to $306 million in the June quarter. The business is closely watched as the company works to cut its reliance on government contracts.
Sales to the U.S. government jumped 53% to $426 million, representing more than 42% of total second-quarter revenue of about $1 billion, which beat estimates.
Last week, the U.S. Army said it might purchase services of up to $10 billion from Palantir over a decade.
Palantir also forecast third-quarter sales above estimates.
The company's second-quarter adjusted earnings of 16 cents per share beat estimates of 14 cents.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

Yahoo

time2 minutes ago

  • Yahoo

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They are also worried about the patent expiration of the firm's mega cancer drug KEYTRUDA and wondering whether Merck & Co., Inc. (NYSE:MRK) will be able to follow up with an equally successful successor. However, the shares did gain 3% this week after Pfizer announced that its bladder cancer drug PADCEV improves survival rates when paired with KEYTRUDA. Cramer was impressed as he commented: 'Look at Merck. I mean, Saint Merck. What a tough, what a tough.' Photo by National Cancer Institute on Unsplash Here are his earlier comments about Merck & Co., Inc. (NYSE:MRK): 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

U.S. Alcohol Consumption Hits 90-Year Low - Zero-Proof Spirits Like Arkay and Beyond Spirits Are Filling the Gap
U.S. Alcohol Consumption Hits 90-Year Low - Zero-Proof Spirits Like Arkay and Beyond Spirits Are Filling the Gap

Yahoo

time2 minutes ago

  • Yahoo

U.S. Alcohol Consumption Hits 90-Year Low - Zero-Proof Spirits Like Arkay and Beyond Spirits Are Filling the Gap

Health-conscious Americans are swapping liquor for plant-based, alcohol-free alternatives Miami, Florida--(Newsfile Corp. - August 15, 2025) - For the first time in nearly a century, alcohol consumption in the United States has fallen to historic lows. A surprising driver behind this shift? Younger, health-conscious consumers who are drinking less - or not at all - in favor of mindful, wellness-oriented lifestyles. This decline in traditional liquor sales is not a sign of the end for social drinking. Instead, it marks the beginning of a new era - one led by zero-proof spirits like Arkay Beverages and Beyond Spirits, the world's first plant-based, alcohol-free whisky. "We are witnessing the biggest drinking culture transformation in 90 years," said Reynald Vito Grattagliano, founder of Arkay Beverages and Beyond Spirits. "Consumers still want the taste, ritual, and social connection of spirits - but without the downsides of alcohol. Our zero-proof innovations deliver exactly that." According to industry analysts, several factors are fueling this trend: Gen Z & Millennials are choosing moderation and alcohol-free lifestyles at unprecedented rates. Health and wellness priorities are shifting spending toward low- and no-alcohol options. Innovation in taste and quality has made zero-proof spirits a viable alternative to traditional liquor. Arkay and Beyond Spirits stand at the forefront of this shift. Arkay offers a wide range of zero-proof alternatives to popular spirits - from whisky and rum to tequila and gin - all made without sugar, artificial sweeteners, or calories. Beyond Spirits takes plant-based innovation to the next level with its alcohol-free whisky crafted from 100% natural, sustainable ingredients. Why Zero-Proof Spirits Are the Future: Social without the hangover: Enjoy the experience of a night out without next-day regrets. Inclusive drinking culture: Alcohol-free options allow everyone to participate - from sober-curious to designated drivers. Better for body and mind: Supports mental clarity, fitness goals, and overall wellness. "This isn't a fad - it's a global movement," added Grattagliano. "Alcohol consumption may be at a 90-year low, but social connection and celebration are stronger than ever. Zero-proof spirits are the bridge between tradition and tomorrow." As Americans turn away from liquor, brands like Arkay and Beyond Spirits are proving that the future of drinking is not about alcohol - it's about choice, health, and innovation. About Arkay Beverages Founded in 2011, Arkay Beverages pioneered the zero-proof spirits category, offering alcohol-free alternatives to classic liquors. Each product is crafted to deliver the authentic taste of spirits without alcohol, sugar, or calories. About Beyond Spirits Beyond Spirits is the creator of the world's first plant-based, alcohol-free whisky. Combining innovation, sustainability, and craftsmanship, the brand delivers a premium drinking experience for health-conscious consumers worldwide. Press Contact: Person Name:Reynald Vito Grattagliano Media RelationsArkay Beverages & Beyond SpiritsEmail: press@ | To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer
Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

Yahoo

time2 minutes ago

  • Yahoo

Pfizer Inc. (PFE) Comes Up With A Good Thing But No One Cares, Laments Jim Cramer

We recently published . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)'s shares jumped by 1.8% earlier this week after the firm announced that its bladder cancer drug Padcev helped improve bladder cancer survival rates when combined with Merck's well-known cancer treatment, KEYTRUDA. The gains were a much-needed boost to the stock, which is still down by 5.6% year-to-date, as the firm has struggled to grow revenue in a turnaround effort led by CEO Albert Bourla. Cramer lamented that Pfizer Inc. (NYSE:PFE)'s stock didn't move higher on the news: 'Bladder cancer. Now that is left over from the Seagen. The Seagen deal, that was supposed to be very, very important. They spent a fortune on Seagen. And I thought the [inaudible] I thought would be a little more just positive. People are not buying the stock. People just feel like, Pfizer comes up with good thing, good thing, good thing, and no one seems to, David, take it as gospel.' Copyright: kadmy / 123RF Stock Photo Cramer discussed Pfizer Inc. (NYSE:PFE) ahead of its earnings: 'There's another one, that I'm not so sure of, reporting at the same time, though, Pfizer. We need to see some really dramatic results here from the clinical trials like the ones that Pfizer picked up when they bought the Seagen at the end of 2023. It's enough time to see more than we've seen already, I gotta tell you that. And they better hurry up because the shareholder base is getting very restive, and who knows what the president has… against this industry.' While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store